BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/6/2021 11:08:06 AM | Browse: 379 | Download: 992
 |
Received |
|
2020-09-08 16:50 |
|
Peer-Review Started |
|
2020-09-08 16:50 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-11-20 06:53 |
|
Revised |
|
2020-12-03 11:55 |
|
Second Decision |
|
2020-12-22 12:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-12-23 05:10 |
|
Articles in Press |
|
2020-12-23 05:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-01-06 23:57 |
|
Typeset the Manuscript |
|
2021-02-04 03:29 |
|
Publish the Manuscript Online |
|
2021-02-06 11:08 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Shu-Yan He, Qing-Feng Lin, Jie Chen, Gui-Ping Yu, Jun-Ling Zhang and Dong Shen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dong Shen, PhD, Chief Doctor, Department of Medical Oncology, The Jiangyin Clinical College of Xuzhou Medical University, No. 163 Shoushan Road, Jiangyin 214400, Jiangsu Province, China. sdshendong@126.com |
| Key Words |
EGFR G724S and R776H; Afatinib; Non-small-cell lung cancer; Case report |
| Core Tip |
EGFR represents the first identified targetable oncogenic driver discovered in NSCLC. The most common EGFR mutations are in-frame deletions in exon 19 and exon 21. However, rare mutations were found in nearly 10-15% of EGFR-positive NSCLC and NSCLC with rare co-mutations had significantly different responses to EGFR TKI. Herein, we described a rare case of rare EGFR G724S/R776H mutations and amplification in a NSCLC responding to afatinib. |
| Publish Date |
2021-02-06 11:08 |
| Citation |
He SY, Lin QF, Chen J, Yu GP, Zhang JL, Shen D. Efficacy of afatinib in patients with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report. World J Clin Cases 2021; 9(6): 1329-1335 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i6/1329.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i6.1329 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
